Establishment and validation of a nomogram model for riskprediction of hepatic encephalopathy: a retrospective analysis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 11 2023
Historique:
received: 01 04 2023
accepted: 08 11 2023
medline: 13 11 2023
pubmed: 10 11 2023
entrez: 9 11 2023
Statut: epublish

Résumé

To establish a high-quality, easy-to-use, and effective risk prediction model for hepatic encephalopathy, to help healthcare professionals with identifying people who are at high risk of getting hepatic encephalopathy, and to guide them to take early interventions to reduce the occurrence of hepatic encephalopathy. Patients (n = 1178) with decompensated cirrhosis who attended the First Affiliated Hospital of Guangxi University of Chinese Medicine between January 2016 and June 2022 were selected for the establishment and validation of a nomogram model for risk prediction of hepatic encephalopathy. In this study, we screened the risk factors for the development of hepatic encephalopathy in patients with decompensated cirrhosis by univariate analysis, LASSO regression and multifactor analysis, then established a nomogram model for predicting the risk of getting hepatic encephalopathy for patients with decompensated cirrhosis, and finally performed differentiation analysis, calibration analysis, clinical decision curve analysis and validation of the established model. A total of 1178 patients with decompensated cirrhosis who were hospitalized and treated at the First Affiliated Hospital of Guangxi University of Chinese Medicine between January 2016 and June 2022 were included for modeling and validation. Based on the results of univariate analysis, LASSO regression analysis and multifactor analysis, a final nomogram model with age, diabetes, ascites, spontaneous peritonitis, alanine transaminase, and blood potassium as predictors of hepatic encephalopathy risk prediction was created. The results of model differentiation analysis showed that the AUC of the model of the training set was 0.738 (95% CI 0.63-0.746), while the AUC of the model of the validation set was 0.667 (95% CI 0.541-0.706), and the two AUCs indicated a good discrimination of this nomogram model. According to the Cut-Off value determined by the Jorden index, when the Cut-Off value of the training set was set at 0.150, the sensitivity of the model was 72.8%, the specificity was 64.8%, the positive predictive value was 30.4%, and the negative predictive value was 91.9%; when the Cut-Off value of the validation set was set at 0.141, the sensitivity of the model was 69.7%, the specificity was 57.3%, the positive predictive value was 34.5%, and the negative predictive value was 84.7%. The calibration curve and the actual events curve largely overlap at the diagonal, indicating that the prediction with this model has less error. The Hosmer-Lemeshow test for goodness of fit was also applied, and the results showed that for the training set, χ

Identifiants

pubmed: 37945916
doi: 10.1038/s41598-023-47012-z
pii: 10.1038/s41598-023-47012-z
pmc: PMC10636098
doi:

Substances chimiques

Potassium RWP5GA015D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19544

Informations de copyright

© 2023. The Author(s).

Références

World J Gastroenterol. 2013 Dec 14;19(46):8745-51
pubmed: 24379595
Hepatol Res. 2015 Sep;45(9):994-1003
pubmed: 26234673
Dig Dis Sci. 2018 Jul;63(7):1952-1961
pubmed: 29691779
Am J Gastroenterol. 2020 Nov;115(11):1775-1785
pubmed: 33156095
Brain Behav. 2021 Feb;11(2):e01970
pubmed: 33236529
BMC Gastroenterol. 2018 Dec 3;18(1):179
pubmed: 30509201
Clin Liver Dis. 2021 May;25(2):393-417
pubmed: 33838857
Dig Dis Sci. 2017 Aug;62(8):1855-1871
pubmed: 28501971
PLoS Negl Trop Dis. 2021 Oct 15;15(10):e0009834
pubmed: 34653175
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e587-e593
pubmed: 35048651
Front Med (Lausanne). 2021 Jun 16;8:692669
pubmed: 34222294
J Clin Epidemiol. 2020 Oct;126:207-216
pubmed: 32712176
Hepatology. 2018 Oct;68(4):1498-1507
pubmed: 29091289
J Hepatol. 2014 Sep;61(3):642-59
pubmed: 25015420
Eur J Cardiothorac Surg. 2019 Feb 1;55(2):179-185
pubmed: 30596979
Transplant Proc. 2014 Jan-Feb;46(1):184-91
pubmed: 24507049
Dig Dis Sci. 2006 Feb;51(2):359-64
pubmed: 16534681
J Dig Dis. 2022 Aug;23(8-9):516-526
pubmed: 36208036
World J Gastroenterol. 2022 Aug 14;28(30):4133-4151
pubmed: 36157113
Cardiovasc Intervent Radiol. 2021 Oct;44(10):1597-1608
pubmed: 34240232
JAMA. 2023 May 9;329(18):1589-1602
pubmed: 37159031
J Clin Transl Hepatol. 2021 Oct 28;9(5):647-654
pubmed: 34722179
Aliment Pharmacol Ther. 2019 Nov;50(10):1112-1119
pubmed: 31583743
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
Hepatology. 2000 Apr;31(4):864-71
pubmed: 10733541
BMJ. 2020 Mar 18;368:m441
pubmed: 32188600
Public Health Nutr. 2021 Feb;24(3):449-456
pubmed: 32753089
Front Med (Lausanne). 2022 Nov 16;9:1035699
pubmed: 36465934
Hepatology. 1991 Mar;13(3):460-6
pubmed: 1999317
Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):275-85
pubmed: 23292084
Int Immunopharmacol. 2022 Jul;108:108879
pubmed: 35623289
Sci Rep. 2020 Jun 10;10(1):9381
pubmed: 32523059
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):575-594
pubmed: 35535075
Dig Liver Dis. 2019 Mar;51(3):425-433
pubmed: 30241795
J Clin Transl Hepatol. 2021 Aug 28;9(4):514-520
pubmed: 34447680

Auteurs

Chun Yao (C)

Guangxi University of Chinese Medicine, Nanning, 530001, Guangxi, People's Republic of China.

Liangjiang Huang (L)

Guangxi University of Chinese Medicine, Nanning, 530001, Guangxi, People's Republic of China.

Meng Wang (M)

First Affiliated Hospital of Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530001, Guangxi, People's Republic of China.

Dewen Mao (D)

First Affiliated Hospital of Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530001, Guangxi, People's Republic of China.

Minggang Wang (M)

First Affiliated Hospital of Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530001, Guangxi, People's Republic of China.

Jinghui Zheng (J)

Guangxi University of Chinese Medicine, Nanning, 530001, Guangxi, People's Republic of China.

Fuli Long (F)

First Affiliated Hospital of Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530001, Guangxi, People's Republic of China.

Jingjing Huang (J)

First Affiliated Hospital of Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530001, Guangxi, People's Republic of China.

Xirong Liu (X)

First Affiliated Hospital of Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530001, Guangxi, People's Republic of China.

Rongzhen Zhang (R)

First Affiliated Hospital of Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530001, Guangxi, People's Republic of China.

Jiacheng Xie (J)

Guangxi University of Chinese Medicine, Nanning, 530001, Guangxi, People's Republic of China.

Chen Cheng (C)

First Affiliated Hospital of Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530001, Guangxi, People's Republic of China.

Fan Yao (F)

First Affiliated Hospital of Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530001, Guangxi, People's Republic of China.

Guochu Huang (G)

First Affiliated Hospital of Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530001, Guangxi, People's Republic of China. 349661907@qq.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH